SpringWorks Free Cash Flow Per Share vs Free Cash Flow Yield Analysis

SWTX Stock

USD 38.91 2.61 7.19%

SpringWorks Therapeutics financial indicator trend analysis is much more than just breaking down SpringWorks Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SpringWorks Therapeutics is a good investment. Please check the relationship between SpringWorks Therapeutics Free Cash Flow Per Share and its Free Cash Flow Yield accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Free Cash Flow Per Share vs Free Cash Flow Yield

Free Cash Flow Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SpringWorks Therapeutics Free Cash Flow Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have almost identical trend.

The correlation between SpringWorks Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield is 0.95. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of SpringWorks Therapeutics, assuming nothing else is changed. The correlation between historical values of SpringWorks Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of SpringWorks Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Free Cash Flow Per Share i.e., SpringWorks Therapeutics' Free Cash Flow Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from SpringWorks Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SpringWorks Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.At this time, SpringWorks Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 38.08 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 237.1 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	490K	1.9M	422K	400.9K
Research Development	101.7M	146.1M	150.5M	158.0M

Cost Of Revenue Research Development

SpringWorks Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Preferred Stock Total Equity	Good Will	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.91	0.8	0.53	0.82	0.43	0.7	0.84	0.12	0.19	0.86	0.69	0.64	0.31	0.65	0.28	-0.19	-0.64	-0.64	0.94	0.86	-0.68	-0.89	0.82	0.94	0.95
Other Current Liab	0.91		0.9	0.5	0.92	0.51	0.54	0.75	0.02	0.34	0.78	0.86	0.84	0.3	0.79	0.37	-0.14	-0.84	-0.84	0.76	0.98	-0.52	-0.99	0.94	0.83	0.75
Total Current Liabilities	0.8	0.9		0.41	0.8	0.83	0.42	0.81	-0.34	0.69	0.68	0.89	0.73	-0.13	0.87	0.73	0.3	-0.74	-0.74	0.64	0.86	-0.41	-0.87	0.82	0.7	0.63
Total Stockholder Equity	0.53	0.5	0.41		0.33	0.09	0.63	0.36	-0.31	0.22	0.63	0.28	0.6	0.25	0.45	0.0	-0.13	-0.6	-0.6	0.45	0.35	-0.63	-0.43	0.72	0.48	0.37
Other Liab	0.82	0.92	0.8	0.33		0.43	0.39	0.76	0.09	0.2	0.83	0.76	0.68	0.34	0.66	0.28	-0.21	-0.69	-0.69	0.71	0.9	-0.37	-0.94	0.82	0.82	0.71
Accounts Payable	0.43	0.51	0.83	0.09	0.43		0.16	0.66	-0.64	0.9	0.35	0.67	0.34	-0.65	0.68	0.98	0.76	-0.34	-0.34	0.32	0.47	-0.17	-0.46	0.37	0.34	0.33
Cash	0.7	0.54	0.42	0.63	0.39	0.16		0.46	0.09	0.02	0.56	0.31	0.42	0.31	0.33	0.0	-0.24	-0.43	-0.43	0.69	0.45	-1.0	-0.5	0.52	0.66	0.69
Other Assets	0.84	0.75	0.81	0.36	0.76	0.66	0.46		-0.2	0.38	0.84	0.63	0.52	-0.1	0.48	0.56	0.18	-0.33	-0.33	0.87	0.68	-0.45	-0.73	0.62	0.88	0.84
Short Term Investments	0.12	0.02	-0.34	-0.31	0.09	-0.64	0.09	-0.2		-0.84	-0.07	-0.17	-0.1	0.79	-0.33	-0.7	-0.85	0.08	0.08	0.19	0.15	-0.06	-0.11	-0.07	0.15	0.26
Inventory	0.19	0.34	0.69	0.22	0.2	0.9	0.02	0.38	-0.84		0.15	0.55	0.34	-0.72	0.69	0.92	0.84	-0.4	-0.4	0.02	0.28	-0.03	-0.27	0.33	0.05	0.0
Other Current Assets	0.86	0.78	0.68	0.63	0.83	0.35	0.56	0.84	-0.07	0.15		0.54	0.51	0.25	0.54	0.21	-0.15	-0.52	-0.52	0.83	0.67	-0.54	-0.75	0.75	0.89	0.8
Total Liab	0.69	0.86	0.89	0.28	0.76	0.67	0.31	0.63	-0.17	0.55	0.54		0.73	0.01	0.79	0.58	0.15	-0.74	-0.74	0.5	0.85	-0.3	-0.84	0.77	0.64	0.52
Treasury Stock	0.64	0.84	0.73	0.6	0.68	0.34	0.42	0.52	-0.1	0.34	0.51	0.73		0.31	0.59	0.25	-0.15	-0.8	-0.8	0.53	0.82	-0.4	-0.84	0.91	0.61	0.44
Intangible Assets	0.31	0.3	-0.13	0.25	0.34	-0.65	0.31	-0.1	0.79	-0.72	0.25	0.01	0.31		-0.07	-0.76	-0.98	-0.34	-0.34	0.3	0.35	-0.28	-0.36	0.37	0.34	0.3
Common Stock	0.65	0.79	0.87	0.45	0.66	0.68	0.33	0.48	-0.33	0.69	0.54	0.79	0.59	-0.07		0.6	0.25	-0.88	-0.88	0.37	0.76	-0.32	-0.74	0.78	0.43	0.4
Property Plant Equipment	0.28	0.37	0.73	0.0	0.28	0.98	0.0	0.56	-0.7	0.92	0.21	0.58	0.25	-0.76	0.6		0.85	-0.23	-0.23	0.19	0.33	-0.01	-0.32	0.24	0.19	0.19
Long Term Debt	-0.19	-0.14	0.3	-0.13	-0.21	0.76	-0.24	0.18	-0.85	0.84	-0.15	0.15	-0.15	-0.98	0.25	0.85		0.15	0.15	-0.23	-0.2	0.21	0.21	-0.19	-0.25	-0.23
Preferred Stock Total Equity	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.52	-0.74	-0.8	-0.34	-0.88	-0.23	0.15		1.0	-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Good Will	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.52	-0.74	-0.8	-0.34	-0.88	-0.23	0.15	1.0		-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Net Tangible Assets	0.94	0.76	0.64	0.45	0.71	0.32	0.69	0.87	0.19	0.02	0.83	0.5	0.53	0.3	0.37	0.19	-0.23	-0.38	-0.38		0.72	-0.67	-0.76	0.66	0.96	0.98
Property Plant And Equipment Net	0.86	0.98	0.86	0.35	0.9	0.47	0.45	0.68	0.15	0.28	0.67	0.85	0.82	0.35	0.76	0.33	-0.2	-0.82	-0.82	0.72		-0.43	-0.99	0.89	0.78	0.72
Net Debt	-0.68	-0.52	-0.41	-0.63	-0.37	-0.17	-1.0	-0.45	-0.06	-0.03	-0.54	-0.3	-0.4	-0.28	-0.32	-0.01	0.21	0.41	0.41	-0.67	-0.43		0.48	-0.5	-0.64	-0.67
Retained Earnings	-0.89	-0.99	-0.87	-0.43	-0.94	-0.46	-0.5	-0.73	-0.11	-0.27	-0.75	-0.84	-0.84	-0.36	-0.74	-0.32	0.21	0.81	0.81	-0.76	-0.99	0.48		-0.92	-0.83	-0.74
Non Current Assets Total	0.82	0.94	0.82	0.72	0.82	0.37	0.52	0.62	-0.07	0.33	0.75	0.77	0.91	0.37	0.78	0.24	-0.19	-0.91	-0.91	0.66	0.89	-0.5	-0.92		0.74	0.61
Non Currrent Assets Other	0.94	0.83	0.7	0.48	0.82	0.34	0.66	0.88	0.15	0.05	0.89	0.64	0.61	0.34	0.43	0.19	-0.25	-0.46	-0.46	0.96	0.78	-0.64	-0.83	0.74		0.94
Cash And Short Term Investments	0.95	0.75	0.63	0.37	0.71	0.33	0.69	0.84	0.26	0.0	0.8	0.52	0.44	0.3	0.4	0.19	-0.23	-0.37	-0.37	0.98	0.72	-0.67	-0.74	0.61	0.94

Click cells to compare fundamentals

SpringWorks Therapeutics Account Relationship Matchups

SpringWorks Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	334.8M	576.2M	452.5M	630.2M	725.8M	762.1M
Other Current Liab	9.3M	13.5M	24.2M	38.8M	64.5M	67.7M
Total Current Liabilities	12.0M	17.6M	30.0M	51.0M	78.2M	82.1M
Total Stockholder Equity	322.1M	557.1M	422.4M	(569.9M)	626.2M	657.5M
Accounts Payable	2.7M	1.4M	3.4M	8.0M	7.4M	7.8M
Cash	327.7M	147.1M	104.0M	67.5M	176.1M	184.9M
Other Assets	1.7M	2.6M	3.3M	3.2M	3.7M	2.2M
Other Current Assets	3.7M	9.8M	18.8M	7.5M	12.7M	13.3M
Total Liab	12.8M	19.1M	30.1M	72.1M	99.6M	104.5M
Property Plant Equipment	795K	3.0M	4.2M	18.3M	16.4M	14.7M
Net Tangible Assets	322.1M	557.1M	422.4M	558.2M	641.9M	336.2M
Property Plant And Equipment Net	795K	3.0M	4.2M	18.3M	24.1M	25.3M
Net Debt	(327.7M)	(144.4M)	(102.7M)	(62.2M)	(169.0M)	(177.4M)
Retained Earnings	(73.0M)	(118.6M)	(292.5M)	(569.9M)	(895.0M)	(850.3M)
Non Current Assets Total	3.5M	62.8M	69.6M	30.5M	224.9M	236.1M
Non Currrent Assets Other	1.7M	2.6M	3.3M	3.2M	4.2M	2.5M
Cash And Short Term Investments	327.7M	508.5M	373.5M	597.0M	479.2M	368.0M
Common Stock Shares Outstanding	43.0M	43.3M	48.5M	53.3M	63.1M	49.5M
Liabilities And Stockholders Equity	334.8M	576.2M	452.5M	(497.9M)	725.8M	762.1M
Non Current Liabilities Total	789K	1.5M	129K	21.0M	21.4M	13.9M
Other Stockholder Equity	395.1M	675.6M	715.2M	1.1B	1.5B	1.6B
Net Invested Capital	322.1M	557.1M	422.4M	558.2M	626.2M	386.6M
Long Term Investments	976K	57.2M	62.1M	9.0M	185.3M	194.6M
Property Plant And Equipment Gross	795K	1.1M	5.2M	19.5M	26.7M	28.1M
Total Current Assets	331.4M	513.4M	382.9M	599.8M	500.9M	374.9M
Accumulated Other Comprehensive Income	(334.8M)	41K	(312K)	(767K)	1.2M	1.3M
Net Working Capital	319.4M	495.8M	352.9M	548.7M	422.7M	344.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SpringWorks Free Cash Flow Per Share vs Free Cash Flow Yield Analysis

Free Cash Flow Per Share vs Free Cash Flow Yield

Free Cash Flow Per Share vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Free Cash Flow Yield

SpringWorks Therapeutics fundamental ratios Correlations

SpringWorks Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

SpringWorks Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for SpringWorks Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Preferred Stock Total Equity
Property Plant And Equipment Net	+ 0.98	Other Current Liab
Property Plant Equipment	+ 0.98	Accounts Payable
Cash And Short Term Investments	+ 0.98	Net Tangible Assets
Non Currrent Assets Other	+ 0.96	Net Tangible Assets
Cash And Short Term Investments	+ 0.95	Total Assets

Net Debt	- 1.0	Cash
Retained Earnings	- 0.99	Property Plant And Equipment Net
Retained Earnings	- 0.99	Other Current Liab
Long Term Debt	- 0.98	Intangible Assets
Retained Earnings	- 0.94	Other Liab
Non Current Assets Total	- 0.92	Retained Earnings